what is a glp-1 receptor agonist glp-1_analogs [TUSOM The role of GLP1 receptor

The therapeutic class is experiencing unprecedented demand as prescriber awareness of pleiotropic benefits, including kidney disease event reduction and major adverse cardiovascular event reduction, reshapes treatment algorithms

Semaglutide and liraglutide are injectable GLP-1 receptor agonists that target these incretin receptors to take advantage of the latter effects to promote weight loss

These successes are even more pronounced in those treated with tirzepatide, with nearly 60% of patients losing 20% of their weight and nearly 40% losing even more than 25% of their initial weight (Figure 6B)

Digestive discomfort is rarely a concern at these levels

PMID 40563436

doi: 10.1016/j.medidd.2024.100188